Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06425133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Study acronym: CARE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2024 to Jul 19, 2024
    • Site details revised at 10 of 10 sites
    v3
  2. Eligibility criteria expanded, about 24 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic colorectal cancer by assessing progression-free survival.
Trial Details
NCT Number NCT06425133
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Collaborators: Groupement Interrégional de Recherche Clinique et d'Innovation
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colonic Neoplasms, Colorectal Neoplasms
Enrollment 174 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov